The first clinical trials for a novel coronavirus vaccine have begun with human test subjects, the National Institutes of Health announced Monday.

The study is being run at Kaiser Permanente Washington Health Research Institute in Seattle, Washington with funding from the National Institute of Allergy and Infectious Diseases (NIAID), the institutes said in a lengthy statement.

In all, 45 healthy adults aged between 18 and 55 years old will take part in the test which are expected to run roughly six weeks.

The first participant received the vaccine, which is being called “investigational” at this point in the study,

Read more: US: First coronavirus vaccine trials begin in humans